Oxford Instruments (OXIG) shares jump 5.66% to 2,190p as it expects to beat forecasts
Oxford Instruments said it expects revenue and operating profit for the year to 31 March 2022 to be marginally ahead of its expectations, despite supply chain disruption and cost inflation.
The company said its full year trading performance reflects “good progress” in the second half of the financial year, with continued strong order growth, supported by resilient end-markets and leaving the Company with a healthy order book as it enters the current financial year.
ImmuPharma (IMM) shares jump 59.29% to 8.93p as PK study meets key endpoints
The specialist drug discovery and development company has announced the successful completion of a pharmacokinetic (PK) study of its lead asset Lupuzor, also known as P140, with data demonstrating that the study has met the key endpoints requested by the US FDA.
The data from the study, which forms part of a new optimised international Phase 3 trial of Lupuzor™ in lupus patients, clears a pathway whereby ImmuPharma can start all clinical studies within the P140 platform. In addition to lupus, there is also a planned Phase 2a/3 pivotal trial in
other diseases such as chronic inflammatory demyelinating polyneuropathy.
“This is a significant milestone for ImmuPharma and for shareholders, and recognition of the key investment thesis behind ImmuPharma,” said Chief Executive Officer, Tim McCarthy.
Shearwater Group (SWG) shares rise 26.94% to 139p as it secures significant contract
Shearwater’s group company, Brookcourt Solutions, has secured a new contract win to the potential value of up to c.£21.0m with a leading telecommunications and media company.
The initial, secured value of the contract, across an initial three year term, is £12.9m, with the contract including an option to extend by a further two years for a total further value of c.£8m.
Under the terms of the contract, Brookcourt will provide forensic monitoring solutions, support, maintenance, training and managed services to the telecommunications and media company.
Feedback (FDBK) shares rise 17.24% to 0.825p as it secures two twelve-month contracts
On Tuesday, the company announced that it was awarded two twelve-month contracts to provide its flagship product, Bleepa®, across two NHS Trusts, for a total value of £0.2m.
The first contract follows a successful pilot and co-development on the platform over the last two years, representing its first full-cycle realisation of its pilot-to-contract business model.
Meanwhile, the second contract represents a contract renewal following the success of an initial one-year contract, at a higher value than the initial contract, Feedback told investors. It said these contracts are early evidence of the success of the company’s 2019 strategic shift.